NCT04105959 is a Phase 1 clinical trial of RIST4721 in Inflammatory Response, sponsored by Aristea Therapeutics, Inc..

Who is sponsoring NCT04105959?

NCT04105959 is sponsored by Aristea Therapeutics, Inc..

What drugs are being tested in NCT04105959?

Interventions in NCT04105959: RIST4721, Placebo.

What condition does NCT04105959 study?

NCT04105959 studies Inflammatory Response.

Is NCT04105959 still recruiting?

NCT04105959 is currently completed. Last updated 29 June 2020.

Last reviewed 2020-06-29 · How we verify

NCT04105959

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Investigate the Effects of RIST4721 on the Inflammatory Response in Healthy Male Subjects Using a Blister Model

Completed Phase 1 Last updated 29 June 2020

What this trial tests

Phase 1 trial testing RIST4721 in Inflammatory Response in 32 participants. Completed in 9 December 2019.

Timeline

25 July 2019

Primary endpoint
19 November 2019

9 December 2019

Quick facts

Lead sponsor	Aristea Therapeutics, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	32
Start date	25 July 2019
Primary completion	19 November 2019
Estimated completion	9 December 2019
Sites	1 location across United Kingdom

Drugs / interventions tested

RIST4721 — full drug profile →
Placebo

Conditions studied

Inflammatory Response — all drugs for Inflammatory Response →

Sponsor

Aristea Therapeutics, Inc. — full company profile →

Who can join

Adults 18 to 55, male only, with Inflammatory Response. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Randomised, Single-Blind, Placebo-Controlled, Crossover Study to Investigate the Effects of RIST4721, a Novel CXCR2 Inhibitor, on the Inflammatory Response in Healthy Male Subjects Using a Standardized Blister Model

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention.
Cambier S, Gouwy M, Proost P. · · 2023 · cited 387× · PMID 36725964 · DOI 10.1038/s41423-023-00974-6
Role of chemokine systems in cancer and inflammatory diseases.
Li H, Wu M, Zhao X. · · 2022 · cited 85× · PMID 35702353 · DOI 10.1002/mco2.147
CXCR2 chemokine receptor - a master regulator in cancer and physiology.
Lazennec G, Rajarathnam K, Richmond A. · · 2024 · cited 53× · PMID 37872025 · DOI 10.1016/j.molmed.2023.09.003
The Clinical Significance and Role of CXCL1 Chemokine in Gastrointestinal Cancers.
Korbecki J, Bosiacki M, Barczak K, Łagocka R, et al · · 2023 · cited 31× · PMID 37408240 · DOI 10.3390/cells12101406
G-Protein-Coupled Receptors in Rheumatoid Arthritis: Recent Insights into Mechanisms and Functional Roles.
Zhao J, Wei K, Jiang P, Chang C, et al · · 2022 · cited 16× · PMID 35874704 · DOI 10.3389/fimmu.2022.907733

Verify or expand the search:

Other trials of RIST4721

Trials testing the same drug.

NCT05448391 — A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF) · Phase 2 · withdrawn
NCT05348681 — A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS) · Phase 2 · terminated
NCT05194839 — A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) · Phase 2 · terminated
NCT03988335 — A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) · Phase 2 · completed

Other recruiting trials for Inflammatory Response

Currently open trials in the same condition.

NCT06450704 — Cerebral and Anti-inflammatory Response Through Exercise - Mechanisms In Depressive Disorders · NA · recruiting
NCT06519487 — Social Experiences and Demographic Factors in the Regulation of Immune Cells · NA · recruiting
NCT06434701 — Severe COVID-19 Infection in Children Presenting to EDs in Israel and England · NA · recruiting
NCT06491966 — Clinical Outcomes and Inflammatory Responses in Viral vs. Bacterial Sepsis · recruiting
NCT06342024 — Pistachio Consumption on Inflammatory Markers and Lean Body Mass · NA · active not recruiting

Other Aristea Therapeutics, Inc. trials

Trials by the same sponsor.

NCT05448391 — A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF) · Phase 2 · withdrawn
NCT05348681 — A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS) · Phase 2 · terminated
NCT05194839 — A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) · Phase 2 · terminated
NCT05023811 — A Study of the ADME of [14C]RIST4721 in Healthy Male Subjects · Phase 1 · completed
NCT03988335 — A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04105959 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aristea Therapeutics, Inc.
Last refreshed: 29 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04105959.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing